Boo, I am calling bullshit on your post #61863.

Boo, I am calling bullshit on your post #61863. You tried to soft pedal your statement by stating you are not a doctor or scientist but it doesn't take being one of those to know the difference between oral and anal. You have stated that Bio's are your passion and that you are a swing trader. Drano in post # 61868 did a nice job of correcting your misrepresentation of the facts but he is a lot more polite than I am about giving you the benefit of a doubt. You have been around since 2012 and have over 2000 posts, many of them on IPIX. Last February I asked you to be more careful with misrepresentations. Today's post is strike 2. Misrepresentations of the facts (lies) and false narratives are TOS violations. If it was a mistake than you need to reread your posts before hitting the send button. If it was not a mistake than cut it out because it will not be tolerated on this board.
=======================
Posted On: 02/11/2019 2:07:34 PM

Posted By: BooDog

Re: petemantx #53179

I was trying to remember the other OTC company that sparked a funding deal. It was RZLT
https://investorshangout.com/recentnews/RZLT

I do believe if IPIX sparks a deal Leo would state much better terms than they did.

Just need to get'r done.


Read More: https://investorshangout.com/post/view?id=534...z6BysScSC1
====================
Posted On: 02/11/2019 3:46:51 PM

Posted By: Mo

Re: BooDog #53183

BooDog, Are you serious with your RZLT comparison??? First off the RZLT deal is not a license deal with Big Pharma. It is a Private Placement deal which in no way should be compared to a license deal. The RZLT deal is dilutive and could be compared to an MFO funding deal but certainly not what we are expecting or what Bertolino stated in today's PR :

“We are active in advanced discussions with a variety of pharmaceuticals companies. Our goal remains to secure a partner for advanced clinical development of Brilacidin as a new therapeutic for Oral Mucositis and Inflammatory Bowel Disease. At that time, we intend to focus our resources on the next stages of development for Brilacidin, notably dermatologic indications, and Kevetrin as a novel anti-cancer agent to build upon the completed studies.”.

Does the above sound like a dilutive funding deal ? Ending your BS post with a "Leo would state much better terms" doesn't cut it. Hopefully it was an honest mistake of not doing diligence and not a case of soft bashing.


Read More: https://investorshangout.com/post/view?id=534...z6ByrbuX00